Latest Insights - page 6 | BiopharmaTrend

Ginkgo Opens Its Robot Lab to Researchers Through a Web Browser

Ginkgo Bioworks has introduced Ginkgo Cloud Lab, an AI-powered interface that allows scientists to submit experimental protocols through a website and run them on Ginkgo’s internal automated lab in Boston. …

Continue ›››

Outpost Bio Raises $3.5M to Make the Human Microbiome “Computable”

London- and Boston-based Outpost Bio has secured $3.5 million in pre-seed financing to build a platform that links experimental microbiology with machine learning models of the human microbiome.

Continue ›››

Five Drugmakers, Including Recursion & Servier, Team Up On Privacy-Preserving ADMET Network

Five pharmaceutical companies, including Lundbeck, Orion Pharma, Recursion, Servier, and one undisclosed organization, have committed around 80% of their internal ADMET datasets to a privacy-preserving federated learning network coordinated by …

Continue ›››

AI Protein Biotech Generate:Biomedicines Lands $400 IPO, Biggest in a While

The Flagship Pioneering-founded Generate Biomedicines has sold 25 million shares at $16 per share under the ticker GENB, raising $400 million, with the potential to reach $460 million if underwriters …

Continue ›››

Eli Lilly Launches Pharma’s Largest AI Supercomputer

Eli Lilly has brought online LillyPod, described to be the industry’s biggest AI supercomputing system, designed to support drug discovery, genomics, and clinical development at scale. The infrastructure, built on …

Continue ›››

Cancer as a Data Problem: What AI Is Doing in Oncology

We track what has moved from promise to proximate execution, from AI-assisted candidate design with 2026 trial targets to agentic workflows that aim to handle multi-step oncology research tasks. Cancer …

Continue ›››

Brain Organoid Gene Therapy Reaches First Patient in Pitt Hopkins Syndrome Trial

Mahzi Therapeutics has begun clinical testing of MZ-1866 for Pitt Hopkins syndrome, an experimental gene therapy developed & tested using human brain organoids, with the first patient dosed in a …

Continue ›››

New Brain Health Clinic Network Combining Care, Research, and AI: Salma Health Launches with $80M

Salma Health has launched as a brain health clinic network backed by $80 million in Series A funding co-led by Mubadala Capital and ARCH Venture Partners. The company says it …

Continue ›››

BreezeBio Raises $60M to Put Its Organ-Targeting Gene Delivery Tech to the Test

BreezeBio, formerly GenEdit, has secured $60 million in Series B financing, led by Yuanta Investment and DSC Investment, with participation from SV Investment, Kiwoom Investment, STIC Ventures, Top Harvest Capital, …

Continue ›››

BEACON Launches to Unite AI Benchmarking Across Biology and Drug Discovery

A new international consortium, BEACON (Benchmarking, Evaluation, and Assessment Consortium for Science), has been launched to align and expand benchmarking efforts across AI-driven biology and medicine. The initiative brings together …

Continue ›››

IQVIA Acquires Charles River Discovery Services Assets, Expanding In Vitro and AI Drug Discovery Capabilities

IQVIA has entered into an agreement to acquire selected drug discovery assets from Charles River Laboratories for approximately $145 million in cash, with up to $10 million in potential additional …

Continue ›››

Recursion Logs Fifth Sanofi Milestone, Says Joint Immunology-Oncology Portfolio Has Potential for 15 Programs

Salt Lake City clinical-stage AI drug developer Recursion reported a fifth progress-based milestone in its collaboration with Sanofi, bringing total payments under that partnership to $134 million to date. The company …

Continue ›››